SCHEMBL2159884

SCHEMBL2159884

CCCCCCc1ccc(Nc2nc(N)c3ncn([C@H]4C[C@H](O)[C@@H](CO)O4)c3n2)cc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNP P00491 1/20 0.52
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
HTT P42858 1/20 0.52
PDE4D Q08499 1/20 0.52
PDE3A Q14432 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
POLA1 P09884 1/20 0.52
CYP1A2 P05177 2/20 0.46
ADORA2A P29274 2/20 0.46
ADORA2B P29275 2/20 0.46
THPO P40225 1/20 0.46
MEN1 O00255 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
BLM P54132 1/20 0.46
ADORA3 P0DMS8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12396110 1.00 PNP (0.52) PNPLMNATP53HTTPDE4D
SCHEMBL2159905 1.00 PNP (0.52) PNPLMNATP53HTTPDE4D
SCHEMBL12396112 0.92 POLA1 (0.43) PNPLMNATP53HTTPDE4D
SCHEMBL2158959 0.90 POLA1 (0.43) PNPLMNATP53HTTPDE4D
SCHEMBL5983794 0.77 PNP (0.72) PNPLMNATP53HTTPDE4D
SCHEMBL5983803 0.77 PNP (0.72) PNPLMNATP53HTTPDE4D
SCHEMBL3940787 0.73 PNP (0.78) PNPLMNATP53HTTPDE4D
SCHEMBL998385 0.73 PNP (0.78) PNPLMNATP53HTTPDE4D
SCHEMBL14520361 0.73 PNP (0.68) PNPLMNATP53HTTPDE4D
SCHEMBL4948967 0.73 CYP1A2 (0.49) PNPLMNATP53HTTPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110182973-A1 POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS FREIE UNIVERSITAET BERLIN (DE) 2011-07-28 US claimed
US-20110182973-A1 POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS FREIE UNIVERSITAET BERLIN (DE) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182973-A1 POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS POLH, POLI, POLK PNP 448/4885LMNA 634/4885TP53 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.